Update in neonatal diabetes

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 17, Issue 1, 2010, Pages 13-19

  Greeley, Siri Atma W ^a   Tucker, Susan E ^a   Worrell, Helen I ^a   Skowron, Kinga B ^a   Bell, Graeme I ^a   Philipson, Louis H ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Diabetes genetics; Monogenic diabetes; Permanent neonatal diabetes; Transient neonatal diabetes

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; GLUCOKINASE; INITIATION FACTOR 2ALPHA; INSULIN; PROTEIN SUBUNIT; SULFONYLUREA DERIVATIVE; TRANSCRIPTION FACTOR FOXP3;

CHROMOSOME 6Q; CHROMOSOME ABERRATION; CLINICAL FEATURE; DIABETES MELLITUS; ENTEROPATHY; EPILEPSY; GENE MUTATION; HUMAN; IMMUNE DYSREGULATION; INSULIN RELEASE; NEUROLOGIC DISEASE; PATIENT IDENTIFICATION; POLYENDOCRINOPATHY; REVIEW;

CHROMOSOMES, HUMAN, PAIR 6; DEVELOPMENTAL DISABILITIES; DIABETES MELLITUS, TYPE 1; EIF-2 KINASE; EPILEPSY; FORKHEAD TRANSCRIPTION FACTORS; GLUCOKINASE; HUMANS; HYPOGLYCEMIC AGENTS; INFANT, NEWBORN; INSULIN; INSULIN-SECRETING CELLS; KATP CHANNELS; MUTATION; SULFONYLUREA COMPOUNDS; SYNDROME;

EID: 75149147180     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e328334f158     Document Type: Review

References (75)

1. Shield JP, Gardner RJ, Wadsworth EJ, et al. Aetiopathology and genetic basis of neonatal diabetes. Arch Dis Child Fetal Neonatal Ed 1997; 76:F39-F42.
2. Stanik J, Gasperikova D, Paskova M, et al. Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers. J Clin Endocrinol Metab 2007; 92:1276-1282.
3. Wiedemann B, Schober E, Waldhoer T, et al. Incidence of neonatal diabetes in Austria-calculation based on the Austrian Diabetes Register. Pediatr Diabetes 2009; (in press).
4. Slingerland AS, Shields BM, Flanagan SE, et al. Referral rates for diagnostic testing support an incidence of permanent neonatal diabetes in three European countries of at least 1 in 260,000 live births. Diabetologia 2009; 52:1683-1685.
5. Milner RD, Ferguson AW, Naidu SH. Aetiology of transient neonatal diabetes. Arch Dis Child 1971; 46:724-726.
6. Gloyn AL, Cummings EA, Edghill EL, et al. Permanent neonatal diabetes due to paternal germline mosaicism for an activating mutation of the KCNJ11 gene encoding the Kir6.2 subunit of the beta-cell potassium adenosine triphosphate channel. J Clin Endocrinol Metab 2004; 89:3932-3935.
7. Edghill EL, Gloyn AL, Goriely A, et al. Origin of de novo KCNJ11 mutations and risk of neonatal diabetes for subsequent siblings. J Clin Endocrinol Metab 2007; 92:1773-1777.
8. Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004; 350:1838-1849.
9. Pearson ER, Flechtner I, Njolstad PR, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006; 355:467-477.
10. Babenko AP, Polak M, Cave H, et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 2006; 355:456-466.
11. Ellard S, Bellanne-Chantelot C, Hattersley AT. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia 2008; 51:546-553.
12. Stoy J, Greeley SA, Paz VP, et al. Diagnosis and treatment of neonatal diabetes: an United States experience. Pediatr Diabetes 2008; 9:450-459.
13. Hattersley A, Bruining J, Shield J, et al. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes 2009; 10 (Suppl 12):33-42.
14. Stoy J, Edghill EL, Flanagan SE, et al. Insulin gene mutations as a cause of permanent neonatal diabetes. Proc Natl Acad Sci U S A 2007; 104:15040-15044.
15. Colombo C, Porzio O, Liu M, et al. Seven mutations in the human insulin gene linked to permanent neonatal/infancy-onset diabetes mellitus. J Clin Invest 2008; 118:2148-2156.
16. Edghill EL, Flanagan SE, Patch AM, et al. Insulin mutation screening in 1,044 patients with diabetes: mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood. Diabetes 2008; 57:1034-1042.
17. Molven A, Ringdal M, Nordbo AM, et al. Mutations in the insulin gene can cause MODY and autoantibody-negative type 1 diabetes. Diabetes 2008; 57:1131-1135.
18. Polak M, Dechaume A, Cave H, et al. Heterozygous missense mutations in the insulin gene are linked to permanent diabetes appearing in the neonatal period or in early infancy: a report from the French ND (Neonatal Diabetes) Study Group. Diabetes 2008; 57:1115-1119.
19. Bonfanti R, Colombo C, Nocerino V, et al. Insulin gene mutations as cause of diabetes in children negative for five type 1 diabetes autoantibodies. Diabetes Care 2009; 32:123-125.
20. Vaxillaire M, Dechaume A, Busiah K, et al. New ABCC8 mutations in relapsing neonatal diabetes and clinical features. Diabetes 2007; 56: 1737-1741.
21. Murphy R, Ellard S, Hattersley AT. Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab 2008; 4:200-213.
22. Ashcroft FM, Proks P, Smith PA, et al. Stimulus-secretion coupling in pancreatic β-cells. J Cell Biochem 1994; 55S:54-65.
23. Froguel P, Zouali H, Vionnet N, et al. Familial hyperglycemia due to mutations in glucokinase: definition of a subtype of diabetes-mellitus. N Engl J Med 1993; 328:697-702.
24. Njolstad PR, Sovik O, Cuesta-Munoz A, et al. Neonatal diabetes mellitus due to complete glucokinase deficiency. N Engl J Med 2001; 344:1588-1592.
25. Glaser B, Kesavan P, Heyman M, et al. Familial hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med 1998; 338:226-230.
26. Inagaki N, Gonoi T, Clement JP IV, et al. Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science 1995; 270:1166-1170.
27. Sharma N, Crane A, Gonzalez G, et al. Familial hyperinsulinism and pancreatic beta-cell ATP-sensitive potassium channels. Kidney Int 2000; 57:803-808.
28. Sagen JV, Raeder H, Hathout E, et al. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes 2004; 53:2713-2718.
29. Henquin JC. Pathways in beta-cell stimulus-secretion coupling as targets for therapeutic insulin secretagogues. Diabetes 2004; 53 (Suppl 3:S48-S58.
30. Ammala C, Ashcroft FM, Rorsman P. Calcium-independent potentiation of insulin release by cyclic AMP in single beta-cells. Nature 1993; 363:356-358.
31. Aguilar-Bryan L, Bryan J. Neonatal diabetes mellitus. Endocr Rev 2008; 29:265-291.
32. Klupa T, Edghill EL, Nazim J, et al. The identification of a R201H mutation in KCNJ11, which encodes Kir6.2, and successful transfer to sustained-release sulphonylurea therapy in a subject with neonatal diabetes: evidence for heterogeneity of beta cell function among carriers of the R201H mutation. Diabetologia 2005; 48:1029-1031.
33. Rica I, Luzuriaga C, Perez de Nanclares G, et al. The majority of cases of neonatal diabetes in Spain can be explained by known genetic abnormalities. Diabet Med 2007; 24:707-713.
34. Suzuki S, Makita Y, Mukai T, et al. Molecular basis of neonatal diabetes in Japanese patients. J Clin Endocrinol Metab 2007; 92:3979-3985.
35. Tonini G, Bizzarri C, Bonfanti R, et al. Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene. Diabetologia 2006; 49:2210-2213.
36. Monaghan MC, Stoy J, Streisand R, et al. Case study: transitioning from insulin to glyburide in permanent neonatal diabetes -medical and psychosocial challenges in an 18-year-old male. Clin Diabet 2009; 27:25-29.
37. Delvecchio M, Zecchino C, Faienza MF, et al. Sulfonylurea treatment in a girl with neonatal diabetes (KCNJ11 R201H) and celiac disease: impact of low compliance to the gluten free diet. Diabetes Res Clin Pract 2009; 84:332-334.
38. Kumaraguru J, Flanagan SE, Greeley SA, et al. Tooth discoloration in patients with neonatal diabetes after transfer onto glibenclamide: a previously unreported side-effect. Diabetes Care 2009; 32:1428-1430.
39. Proks P, Girard C, Haider S, et al. A gating mutation at the internal mouth of the Kir6.2 pore is associated with DEND syndrome. EMBO Rep 2005; 6:470-475.
40. Gloyn AL, Diatloff-Zito C, Edghill EL, et al. KCNJ11 activating mutations are associated with developmental delay, epilepsy and neonatal diabetes syndrome and other neurological features. Eur J Hum Genet 2006; 14:824-830.
41. Flanagan SE, Edghill EL, Gloyn AL, et al. Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the ?rst 6 months of life, with the phenotype determined by genotype. Diabetologia 2006; 49:1190-1197.
42. months of life, with the phenotype determined by genotype. Diabetologia 2006; 49:1190-1197.
43. Shimomura K, Horster F, de Wet H, et al. A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain. Neurology 2007; 69:1342-1349.
44. Proks P, Shimomura K, Craig TJ, et al. Mechanism of action of a sulphonylurea receptor SUR1 mutation (F132L) that causes DEND syndrome. Hum Mol Genet 2007; 16:2011-2019.
45. Mlynarski W, Tarasov AI, Gach A, et al. Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11. Nat Clin Pract Neurol 2007; 3:640-645.
46. Slingerland AS, Nuboer R, Hadders-Algra M, et al. Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene. Diabetologia 2006; 49:2559-2563.
47. Slingerland AS, Hurkx W, Noordam K, et al. Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation. Diabet Med 2008; 25:277-281.
48. Mohamadi A, Clark LM, Lipkin PH, et al. Medical and developmental impact of transition from subcutaneous insulin to oral glyburide in a 15-yr-old boy with neonatal diabetes mellitus and intermediate DEND syndrome: extending the age of KCNJ11 mutation testing in neonatal DM. Pediatr Diabetes 2009; (in press).
49. Koster JC, Cadario F, Peruzzi C, et al. The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy. J Clin Endocrinol Metab 2008; 93:1054-1061.
50. Tammaro P, Flanagan SE, Zadek B, et al. A Kir6.2 mutation causing severe functional effects in vitro produces neonatal diabetes without the expected neurological complications. Diabetologia 2008; 51:802-810.
51. Steiner DF, Park SY, Stoy J, et al. A brief perspective on insulin production. Diabetes Obes Metab 2009; 11 (Suppl 4:189-196.
52. Rubio-Cabezas O, Minton JA, Caswell R, et al. Clinical heterogeneity in patients with FOXP3 mutations presenting with permanent neonatal diabetes. Diabetes Care 2009; 32:111-116.
53. Temple IK, Shield JP. Transient neonatal diabetes, a disorder of imprinting. J Med Genet 2002; 39:872-875.
54. Mackay DJ, Callaway JL, Marks SM, et al. Hypomethylation of multiple imprinted loci in individuals with transient neonatal diabetes is associated with mutations in ZFP57. Nat Genet 2008; 40:949-951.
55. Shield JP, Flanagan SE, Mackay DJ, et al. Mosaic paternal uniparental isodisomy and an ABCC8 gene mutation in a patient with permanent neonatal diabetes and hemihypertrophy. Diabetes 2008; 57:255-258.
56. Gloyn AL, Noordam K, Willemsen MA, et al. Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations. Diabetes 2003; 52:2433-2440.
57. Sayed S, Langdon DR, Odili S, et al. Extremes of clinical and enzymatic phenotypes in children with hyperinsulinism caused by glucokinase activating mutations. Diabetes 2009; 58:1419-1427.
58. Turkkahraman D, Bircan I, Tribble ND, et al. Permanent neonatal diabetes mellitus caused by a novel homozygous (T168A) glucokinase (GCK) mutation: initial response to oral sulphonylurea therapy. J Pediatr 2008; 153:122-126.
59. Matschinsky FM, Magnuson MA, Zelent D, et al. The network of glucokinaseexpressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes 2006; 55:1-12.
60. Shields BM, SpyerG, Slingerland AS, et al. Mutations in the glucokinase gene of the fetus result in reduced placental weight. Diabetes Care 2008; 31:753-757.
61. Singh R, Pearson ER, Clark PM, Hattersley AT. The long-term impact on offspring of exposure to hyperglycaemia in utero due to maternal glucokinase gene mutations. Diabetologia 2007; 50:620-624.
62. Spyer G,Macleod KM, Shepherd M, et al. Pregnancy outcome in patients with raised blood glucose due to a heterozygous glucokinase gene mutation. Diabet Med 2009; 26:14-18.
63. Stoss H, Pesch HJ, Pontz B, et al. Wolcott-Rallison syndrome: diabetes mellitus and spondyloepiphyseal dysplasia. Eur J Pediatr 1982; 138:120-129.
64. Stewart FJ, Carson DJ, Thomas PS, et al. Wolcott-Rallison syndrome associated with congenital malformations and a mosaic deletion 15q 11-12. Clin Genet 1996; 49:152-155.
65. Thornton CM, Carson DJ, Stewart FJ. Autopsy findings in the Wolcott-Rallison syndrome. Pediatr Pathol Lab Med 1997; 17:487-496.
66. Delepine M, Nicolino M, Barrett T, et al. EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat Genet 2000; 25:406-409.
67. Harding HP, Ron D. Endoplasmic reticulum stress and the development of diabetes: a review. Diabetes 2002; 51 (Suppl 3:S455-S461. (Pubitemid 35403430)
68. Feng D, Wei J, Gupta S, et al. Acute ablation of PERK results in ER dysfunctions followed by reduced insulin secretion and cell proliferation. BMC Cell Biol 2009; 10:61.
69. Sovik O, Njolstad PR, Jellum E, Molven A. Wolcott-Rallison syndrome with 3-hydroxydicarboxylic aciduria and lethal outcome. J Inherit Metab Dis 2008; [Epub ahead of print]
70. Engelmann G, Meyburg J, Shahbek N, et al. Recurrent acute liver failure and mitochondriopathy in a case of Wolcott-Rallison syndrome. J Inherit Metab Dis 2008; 31:540-546.
71. Ganesh R, Arvindkumar R, Vasanthi T. Infantile-onset diabetes mellitus: a 1-year follow-up study. Clin Pediatr (Phila) 2009; 48:271-274.
72. Rubio-Cabezas O, Patch AM, Minton JA, et al. Wolcott-Rallison syndrome is the most common genetic cause of permanent neonatal diabetes in consanguineous families. J Clin Endocrinol Metab 2009; 94:4162-4170.
73. D'Amato E, Tammaro P, Craig TJ, et al. Variable phenotypic spectrum of diabetes mellitus in a family carrying a novel KCNJ11 gene mutation. Diabet Med 2008; 25:651-656.
74. Klupa T, Kowalska I, Wyka K, et al. Mutations in the ABCC8 (SUR1 subunit of the K(ATP) channel) gene are associated with a variable clinical phenotype. Clin Endocrinol (Oxf) 2009; 71:358-362.
75. Martin-Frias M, Colino E, Perez de Nanclares G, et al. Glibenclamide treatment in relapsed transient neonatal diabetes as a result of a KCNJ11 activating mutation (N48D). Diabet Med 2009; 26:567-569.